# BioVentrix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioventrix

- Industry: Medical Devices & Equipment
- Headquarters: San Ramon, US
- Website: www.bioventrix.com
- Total disclosed funding: $13M
- Latest round: Series A (Mar 30, 2023)
- Investors on record: 4

## About

BioVentrix is a medical device company focused on innovating treatments for heart conditions, specifically heart failure and ischemic heart disease, by providing advanced cardiac repair systems.BioVentrix develops innovative medical technologies for cardiac repair, particularly addressing heart failure. The company is headquartered in San Ramon, US. Ken Miller serves as the CEO. In March 2023, BioVentrix raised USD 12.65 mn in Series A funding led by Andera Partners, alongside participation from Cormorant Asset Management, Richmond Brothers, Squarepoint Capital, and Taglich Private Equity. This funding supports the company’s efforts to achieve Premarket Approval for its Revivent TC® System which is designed for patients with ischemic heart failure.BioVentrix primarily specializes in innovative medical devices aimed at treating heart conditions, particularly heart failure and ischemic heart disease. Their flagship product, the Revivent TC System, is a unique device designed for the transcatheter repair of the failing heart. This system utilizes a minimally invasive approach to restore the heart's shape and function, thus alleviating symptoms associated with heart failure. The company targets healthcare providers, including hospitals, cardiologists, and cardiac surgeons, who serve patients experiencing severe heart conditions. The Revivent TC System is primarily marketed in North America and select countries in Europe, where there is a significant demand for advanced cardiac interventions.BioVentrix generates revenue through the sale of its specialized medical devices directly to healthcare institutions. Transactions are primarily structured on a B2B basis, where hospitals and clinics procure devices for use in cardiac procedures. Each transaction may involve a one-time purchase or could include service agreements for device support and maintenance. The pricing structure for the Revivent TC System is aligned with industry standards for high-value medical devices, ensuring that clients receive comprehensive solutions for heart treatment. Additional revenue may be generated through partnerships with medical professionals and institutions for training and implementation of the technology in surgical practices.In March 2023, BioVentrix raised USD 12.65 mn in Series A funding led by Andera Partners to support the Premarket Approval of the Revivent TC® System for patients with ischemic heart failure. The company aims to expand its product offerings and penetrate new markets, focusing on regions within North America and Europe where advanced cardiac interventions are increasingly in demand.

## Funding rounds

- Series A, Mar 30, 2023, $13M — Andera Partners, Taglich Private Equity, Cormorant Asset Management, Richmond Brothers

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- Taglich Private Equity (https://capitalatlas.ai/funds/taglich-private-equity) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Richmond Brothers — Series A